273 related articles for article (PubMed ID: 34338690)
21. MYC is sufficient to generate mid-life high-grade serous ovarian and uterine serous carcinomas in a p53-R270H mouse model.
Blackman A; Rees AC; Bowers RR; Jones CM; Vaena SG; Clark MA; Carter S; Villamor ED; Evans D; Emanuel AJ; Fullbright G; Long DT; Spruill L; Romeo MJ; Helke KL; Delaney JR
bioRxiv; 2024 Jan; ():. PubMed ID: 38352443
[TBL] [Abstract][Full Text] [Related]
22. [Current FIGO staging classification for cancer of ovary, fallopian tube and peritoneum].
Šišovská I; Minář L; Felsinger M; Anton M; Bednaříková M; Hausnerová J; Jandáková E; Weinberger V
Ceska Gynekol; 2017; 82(3):230-236. PubMed ID: 28593778
[TBL] [Abstract][Full Text] [Related]
23. Fallopian tube precursors of ovarian low- and high-grade serous neoplasms.
Vang R; Shih IeM; Kurman RJ
Histopathology; 2013 Jan; 62(1):44-58. PubMed ID: 23240669
[TBL] [Abstract][Full Text] [Related]
24. The fallopian tube as the origin of high grade serous ovarian cancer: review of a paradigm shift.
Reade CJ; McVey RM; Tone AA; Finlayson SJ; McAlpine JN; Fung-Kee-Fung M; Ferguson SE
J Obstet Gynaecol Can; 2014 Feb; 36(2):133-140. PubMed ID: 24518912
[TBL] [Abstract][Full Text] [Related]
25. Versican secreted by the ovary links ovulation and migration in fallopian tube derived serous cancer.
Russo A; Yang Z; Heyrman GM; Cain BP; Lopez Carrero A; Isenberg BC; Dean MJ; Coppeta J; Burdette JE
Cancer Lett; 2022 Sep; 543():215779. PubMed ID: 35697329
[TBL] [Abstract][Full Text] [Related]
26. Kallistatin inhibits tumour progression and platinum resistance in high-grade serous ovarian cancer.
Wu H; Li R; Zhang Z; Jiang H; Ma H; Yuan C; Sun C; Li Y; Kong B
J Ovarian Res; 2019 Dec; 12(1):125. PubMed ID: 31884974
[TBL] [Abstract][Full Text] [Related]
27. Cells of origin of ovarian cancer: ovarian surface epithelium or fallopian tube?
Klotz DM; Wimberger P
Arch Gynecol Obstet; 2017 Dec; 296(6):1055-1062. PubMed ID: 28940023
[TBL] [Abstract][Full Text] [Related]
28. Characterization of MicroRNA-200 pathway in ovarian cancer and serous intraepithelial carcinoma of fallopian tube.
Yang J; Zhou Y; Ng SK; Huang KC; Ni X; Choi PW; Hasselblatt K; Muto MG; Welch WR; Berkowitz RS; Ng SW
BMC Cancer; 2017 Jun; 17(1):422. PubMed ID: 28623900
[TBL] [Abstract][Full Text] [Related]
29. No. 344-Opportunistic Salpingectomy and Other Methods of Risk Reduction for Ovarian/Fallopian Tube/Peritoneal Cancer in the General Population.
Salvador S; Scott S; Francis JA; Agrawal A; Giede C
J Obstet Gynaecol Can; 2017 Jun; 39(6):480-493. PubMed ID: 28527613
[TBL] [Abstract][Full Text] [Related]
30. Papillary tubal hyperplasia: the putative precursor of ovarian atypical proliferative (borderline) serous tumors, noninvasive implants, and endosalpingiosis.
Kurman RJ; Vang R; Junge J; Hannibal CG; Kjaer SK; Shih IeM
Am J Surg Pathol; 2011 Nov; 35(11):1605-14. PubMed ID: 21997682
[TBL] [Abstract][Full Text] [Related]
31. Activin A stimulates migration of the fallopian tube epithelium, an origin of high-grade serous ovarian cancer, through non-canonical signaling.
Dean M; Davis DA; Burdette JE
Cancer Lett; 2017 Apr; 391():114-124. PubMed ID: 28115208
[TBL] [Abstract][Full Text] [Related]
32. Epithelialization of mouse ovarian tumor cells originating in the fallopian tube stroma.
Hua Y; Choi PW; Trachtenberg AJ; Ng AC; Kuo WP; Ng SK; Dinulescu DM; Matzuk MM; Berkowitz RS; Ng SW
Oncotarget; 2016 Oct; 7(40):66077-66086. PubMed ID: 27602775
[TBL] [Abstract][Full Text] [Related]
33. miR-145 inhibits tumor growth and metastasis by targeting metadherin in high-grade serous ovarian carcinoma.
Dong R; Liu X; Zhang Q; Jiang Z; Li Y; Wei Y; Li Y; Yang Q; Liu J; Wei JJ; Shao C; Liu Z; Kong B
Oncotarget; 2014 Nov; 5(21):10816-29. PubMed ID: 25333261
[TBL] [Abstract][Full Text] [Related]
34. [The Fallopian tube odyssey: from the ovary to the tube. About high-grade serous ovarian carcinoma].
Chêne G; Dauplat J; Radosevic-Robin N; Cayre A; Penault-Llorca F
Bull Cancer; 2013; 100(7-8):757-64. PubMed ID: 23831931
[TBL] [Abstract][Full Text] [Related]
35. Evidence for lineage continuity between early serous proliferations (ESPs) in the Fallopian tube and disseminated high-grade serous carcinomas.
Soong TR; Howitt BE; Miron A; Horowitz NS; Campbell F; Feltmate CM; Muto MG; Berkowitz RS; Nucci MR; Xian W; Crum CP
J Pathol; 2018 Nov; 246(3):344-351. PubMed ID: 30043522
[TBL] [Abstract][Full Text] [Related]
36. Chromosomal instability in fallopian tube precursor lesions of serous carcinoma and frequent monoclonality of synchronous ovarian and fallopian tube mucosal serous carcinoma.
Salvador S; Rempel A; Soslow RA; Gilks B; Huntsman D; Miller D
Gynecol Oncol; 2008 Sep; 110(3):408-17. PubMed ID: 18597838
[TBL] [Abstract][Full Text] [Related]
37. Low-Stage High-Grade Serous Ovarian Carcinomas: Support for an Extraovarian Origin.
Morency E; Leitao MM; Soslow RA
Int J Gynecol Pathol; 2016 May; 35(3):222-9. PubMed ID: 26630225
[TBL] [Abstract][Full Text] [Related]
38. The Transcoelomic Ecosystem and Epithelial Ovarian Cancer Dissemination.
Ritch SJ; Telleria CM
Front Endocrinol (Lausanne); 2022; 13():886533. PubMed ID: 35574025
[TBL] [Abstract][Full Text] [Related]
39. Exposure of the extracellular matrix and colonization of the ovary in metastasis of fallopian-tube-derived cancer.
Dean M; Jin V; Russo A; Lantvit DD; Burdette JE
Carcinogenesis; 2019 Mar; 40(1):41-51. PubMed ID: 30475985
[TBL] [Abstract][Full Text] [Related]
40. Fallopian Tube-Derived Tumor Cells Induce Testosterone Secretion from the Ovary, Increasing Epithelial Proliferation and Invasion.
Colina JA; Zink KE; Eliadis K; Salehi R; Gargus ES; Wagner SR; Moss KJ; Baligod S; Li K; Kirkpatrick BJ; Woodruff TK; Tsang BK; Sanchez LM; Burdette JE
Cancers (Basel); 2021 Apr; 13(8):. PubMed ID: 33923536
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
